Frontline Osimertinib Approaches European Approval for NSCLC

April 27, 2018 – The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of osimertinib as a first-line treatment for patients with non–small cell lung cancer (NSCLC) whose tumors harbor activating EGFR mutations, according to AstraZeneca, the manufacturer of the third-generation, irreversible EGFR TKI. The CHMP recommendation is based on the phase III FLAURA study, in which frontline … (leggi tutto)